Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals.
Innocan Pharma’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) the research and development of the treatment of Covid-19 (and other viruses causing lung inflammation as well as other central nervous system (CNS) diseases such as epilepsy and Alzheimer’s Disease) by using CBD loaded exosomes (“CLX”); (ii) the research and development of the use of CBD loaded liposomes to provide pain relief and treat epilepsy and other central nervous system disorders and other indications; and (iii) the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain.
Innocan Pharma is led by a multi-disciplinary management and R&D team, headed by:
Iris Bincovich, an experienced healthcare Executive, Ron Mayron, former CEO of Teva, one of the largest generic pharmaceutical companies in the world. Yoram Drucker Founder of two Nasdaq traded companies – Pluristem & Brainstorm, working with stem cells, Nir Avram, former member of the pharma innovation team at Perrigo, Prof. Hezy Barenholz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem and Prof. Daniel Offen, a leading researcher specializing in Neuroscience and Exosome technology, Head of the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University.
Research & Development
Our Best-in-Class Research and Development team has vast expertise in developing CBD-integrated formulations for topical use We have experience in developing sufficiently numbers of formulations, working with clients to tailor formulate, meticulously selecting suitable active ingredients, fragrances, and ensuring that the product meets and exceeds performance expectations.
Our R&D department develops products integrating the most advanced technology and a wide range of the highest quality materials, ingredients, textures and fragrances. We cooperate closely with leading research institutes and global ingredient suppliers to ensure that we are always up to date on the latest trends related to safe, effective, and sustainable ingredients that go into our finished products.
Our R&D team is globally acknowledged for it’s high output of new and innovative products for brand owners and retailers on 5 continents. We identify market trends, customer needs and apply our extensive experience to develop new formulations and assist in packaging recommendation allowing unique consumer benefits.
Innocan Pharma has developed several lines of unique and innovative topical Cannabis formulations. This platform provides the versatility to develop new topical products (both cosmetics & pharmaceutics) for the possible treatment of dermatological and other skin & hair conditions.
Meet our CTO - Nir Avram
Nir Avram is a senior consultant in the areas of pharmaceuticals and cosmetics with over 30 years of experience.
Nir consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations and synthesis of novel materials, to start-ups as well as established companies.
Nir is vice president of research & development at Emilia Resources in the US. Prior to this he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perigo. He holds several patents.